91 related articles for article (PubMed ID: 9804127)
1. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome.
Kawanishi C; Shimoda Y; Fujimaki J; Onishi H; Suzuki K; Hanihara T; Sugiyama N; Kosaka K
J Neurol Sci; 1998 Sep; 160(1):102-4. PubMed ID: 9804127
[TBL] [Abstract][Full Text] [Related]
2. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B.
Kawanishi C; Hanihara T; Maruyama Y; Matsumura T; Onishi H; Inoue K; Sugiyama N; Suzuki K; Yamada Y; Kosaka K
Psychiatr Genet; 1997; 7(3):127-9. PubMed ID: 9323326
[TBL] [Abstract][Full Text] [Related]
3. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity.
Kawanishi C; Furuno T; Onishi H; Sugiyama N; Suzuki K; Matsumura T; Ishigami T; Kosaka K
Psychiatr Genet; 2000 Sep; 10(3):145-7. PubMed ID: 11204351
[TBL] [Abstract][Full Text] [Related]
4. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome.
Kato D; Kawanishi C; Kishida I; Furuno T; Suzuki K; Onishi H; Hirayasu Y
Eur J Clin Pharmacol; 2007 Nov; 63(11):991-6. PubMed ID: 17701031
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report.
Kato D; Kawanishi C; Kishida I; Furuno T; Matsumura T; Hasegawa H; Suzuki K; Hirayasu Y
Psychiatry Clin Neurosci; 2005 Aug; 59(4):504-7. PubMed ID: 16048458
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 HhaI genotype and the neuroleptic malignant syndrome.
Iwahashi K; Yoshihara E; Nakamura K; Ameno K; Watanabe M; Tsuneoka Y; Ichikawa Y; Igarashi K
Neuropsychobiology; 1999; 39(1):33-7. PubMed ID: 9892857
[TBL] [Abstract][Full Text] [Related]
8. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation.
Ochi S; Kawasoe K; Abe M; Fukuhara R; Sonobe K; Kawabe K; Ueno S
Gen Hosp Psychiatry; 2011; 33(6):640.e1-2. PubMed ID: 21749835
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 Hhal genotype and the neuroleptic malignant syndrome (NMS).
Iwahashi K; Nakamura K; Suwaki H; Tsuneoka Y; Ichikawa Y
Clin Chim Acta; 1997 Sep; 265(1):143-4. PubMed ID: 9352138
[No Abstract] [Full Text] [Related]
10. Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency.
Butwicka A; Krystyna S; Retka W; Wolańczyk T
Eur J Pediatr; 2014 Dec; 173(12):1639-42. PubMed ID: 24253372
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P-450 2D6 gene polymorphism is not associated with neuroleptic malignant syndrome.
Ueno S; Otani K; Kaneko S; Koshiro K; Kondoh K; Kotani Y; Sano A
Biol Psychiatry; 1996 Jul; 40(1):72-4. PubMed ID: 8780858
[No Abstract] [Full Text] [Related]
12. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score.
Ellingrod VL; Schultz SK; Arndt S
Psychiatr Genet; 2000 Mar; 10(1):9-11. PubMed ID: 10909122
[TBL] [Abstract][Full Text] [Related]
13. Neuroleptic malignant syndrome in a patient with succinic semialdehyde dehydrogenase deficiency.
Neu P; Seyfert S; Brockmöller J; Dettling M; Marx P
Pharmacopsychiatry; 2002 Jan; 35(1):26-8. PubMed ID: 11819156
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.
Inada T; Senoo H; Iijima Y; Yamauchi T; Yagi G
Psychiatr Genet; 2003 Sep; 13(3):163-8. PubMed ID: 12960748
[TBL] [Abstract][Full Text] [Related]
15. Genetic predisposition to neuroleptic malignant syndrome : implications for antipsychotic therapy.
Kawanishi C
Am J Pharmacogenomics; 2003; 3(2):89-95. PubMed ID: 12749726
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 genotyping in patients on psychoactive drug therapy.
Topić E; Stefanović M; Ivanisević AM; Blazinić F; Culav J; Skocilić Z
Clin Chem Lab Med; 2000 Sep; 38(9):921-7. PubMed ID: 11097351
[TBL] [Abstract][Full Text] [Related]
17. [Risperidone intoxication in a patient with a genetic predisposition as "poor [non]metabolizer"].
Strauss M; Heinritz W; Hegerl U; Kopf A
Psychiatr Prax; 2010 May; 37(4):199-201. PubMed ID: 20225176
[TBL] [Abstract][Full Text] [Related]
18. Is the predisposition to neuroleptic malignant syndrome genetically transmitted?
Otani K; Horiuchi M; Kondo T; Kaneko S; Fukushima Y
Br J Psychiatry; 1991 Jun; 158():850-3. PubMed ID: 1678666
[TBL] [Abstract][Full Text] [Related]
19. NMS and genetic drug oxidation.
Otani K; Kaneko S; Fukushima Y; Chiba K; Ishizaki T
Br J Psychiatry; 1991 Oct; 159():595-6. PubMed ID: 1751888
[No Abstract] [Full Text] [Related]
20. Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome.
Suzuki A; Kondo T; Otani K; Mihara K; Yasui-Furukori N; Sano A; Koshiro K; Kaneko S
Am J Psychiatry; 2001 Oct; 158(10):1714-6. PubMed ID: 11579007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
